CR9379A - Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fq - Google Patents

Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fq

Info

Publication number
CR9379A
CR9379A CR9379A CR9379A CR9379A CR 9379 A CR9379 A CR 9379A CR 9379 A CR9379 A CR 9379A CR 9379 A CR9379 A CR 9379A CR 9379 A CR9379 A CR 9379A
Authority
CR
Costa Rica
Prior art keywords
orphanine
nociceptine
partials
receiver
complete
Prior art date
Application number
CR9379A
Other languages
English (en)
Inventor
Guerrini Remo
Salvadori Severo
Calo Girolamo
Regoli Domenico
Original Assignee
Ufpeptides Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ufpeptides Srl filed Critical Ufpeptides Srl
Publication of CR9379A publication Critical patent/CR9379A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

La presente invencion describe analogos de peptido de nociceptina/orfanina FQ, composiciones de los mismos, y su uso en el tratamiento de trastornos y disfunciones relacionadas con la activacion o bloqueo de receptores NOP.
CR9379A 2005-02-15 2007-09-13 Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fq CR9379A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000003A ITFE20050003A1 (it) 2005-02-15 2005-02-15 Agonisti pieni e parziali ed antagonisti del recettore per nocicettina/orfanina fq ad elevata potenza.

Publications (1)

Publication Number Publication Date
CR9379A true CR9379A (es) 2008-04-25

Family

ID=36685750

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9379A CR9379A (es) 2005-02-15 2007-09-13 Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fq

Country Status (29)

Country Link
US (1) US8227414B2 (es)
EP (1) EP1851241B1 (es)
JP (1) JP5281292B2 (es)
KR (1) KR101294895B1 (es)
CN (2) CN104689293A (es)
AU (1) AU2006215639B2 (es)
BR (1) BRPI0606998B8 (es)
CA (1) CA2598121C (es)
CR (1) CR9379A (es)
CU (1) CU23823A3 (es)
CY (1) CY1116456T1 (es)
DK (1) DK1851241T3 (es)
EA (1) EA011325B1 (es)
ES (1) ES2541308T3 (es)
HR (1) HRP20150731T1 (es)
HU (1) HUE025000T2 (es)
IL (1) IL185235A (es)
IT (1) ITFE20050003A1 (es)
MA (1) MA29288B1 (es)
MX (1) MX2007009523A (es)
NI (1) NI200700205A (es)
NO (1) NO341856B1 (es)
PL (1) PL1851241T3 (es)
PT (1) PT1851241E (es)
RS (1) RS54095B1 (es)
SI (1) SI1851241T1 (es)
UA (1) UA91844C2 (es)
WO (1) WO2006087340A2 (es)
ZA (1) ZA200707714B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITNA20090026A1 (it) * 2009-05-14 2010-11-15 Agostino Bruno D Agonisti del recettore nop e loro usi terapeutici
CN112730849B (zh) * 2021-01-14 2023-03-10 山西医科大学第二医院 内源性孤啡肽作为糖尿病合并无症状性心肌缺血的血清生物标志物的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093294A2 (en) * 2002-04-29 2003-11-13 Euro-Celtique S.A. Conformationally constrained peptides that bind the orl-1 receptor
ITMI20022022A1 (it) * 2002-09-24 2004-03-25 Girolamo Calo' Analoghi di nocicettina.
ITMI20031349A1 (it) 2003-07-01 2005-01-02 Ufpeptides S R L Antagonisti del recettore nop e loro usi terapeutici.
CN1634980A (zh) * 2004-10-10 2005-07-06 兰州大学 孤啡肽的类似物

Also Published As

Publication number Publication date
PT1851241E (pt) 2015-08-28
NO341856B1 (no) 2018-02-12
WO2006087340A2 (en) 2006-08-24
CA2598121C (en) 2014-11-25
BRPI0606998A2 (pt) 2014-01-21
HRP20150731T1 (hr) 2015-08-14
HUE025000T2 (en) 2016-01-28
UA91844C2 (ru) 2010-09-10
KR101294895B1 (ko) 2013-08-08
US20100273710A1 (en) 2010-10-28
RS54095B1 (en) 2015-10-30
CN104689293A (zh) 2015-06-10
CN101128482A (zh) 2008-02-20
EP1851241B1 (en) 2015-04-08
NO20074702L (no) 2007-10-29
ES2541308T3 (es) 2015-07-17
BRPI0606998B1 (pt) 2018-04-10
CY1116456T1 (el) 2017-03-15
SI1851241T1 (sl) 2015-08-31
US8227414B2 (en) 2012-07-24
WO2006087340A8 (en) 2007-06-21
EP1851241A2 (en) 2007-11-07
IL185235A0 (en) 2008-02-09
CU23823A3 (es) 2012-06-21
NI200700205A (es) 2008-06-17
DK1851241T3 (en) 2015-06-29
JP5281292B2 (ja) 2013-09-04
PL1851241T3 (pl) 2015-09-30
WO2006087340A3 (en) 2006-10-26
EA200701732A1 (ru) 2008-02-28
EA011325B1 (ru) 2009-02-27
MA29288B1 (fr) 2008-02-01
IL185235A (en) 2014-08-31
ZA200707714B (en) 2008-06-25
CA2598121A1 (en) 2006-08-24
JP2008530058A (ja) 2008-08-07
AU2006215639B2 (en) 2011-05-26
AU2006215639A1 (en) 2006-08-24
ITFE20050003A1 (it) 2006-08-16
KR20070119614A (ko) 2007-12-20
BRPI0606998B8 (pt) 2021-05-25
MX2007009523A (es) 2007-09-07

Similar Documents

Publication Publication Date Title
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
DE602007012072D1 (de) Orantagonisten
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
CY1113798T1 (el) Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
SV2011003891A (es) Antagonistas de los receptores tipo toll 3
DK1791571T3 (da) Radiofluorinerede peptider
GT200900187A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos
DE602007004999D1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
CL2004000449A1 (es) Compuestos derivados de imidazol-4-il-etinil-piridina, para tratar trastornos mediados por el receptor mglur5; procedimiento de preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
ATE519498T1 (de) Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen
CL2008003602A1 (es) Compuestos derivados de triazolotriazinas y triazolopirazinas sustituidas; composicion farmaceutica; y su uso en el tratamiento y/o profilaxis de trastornos hematologicos.
EA200802104A1 (ru) Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств
CR9379A (es) Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fq
UY31420A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina
UY31421A1 (es) Arilindenopirimidinas y su uso como adenosina a2a
CL2009000317A1 (es) Compuestos derivados de 3-alquil-piperazina sustituida; composicion farmaceutica; y su uso en el tratamiento de la depresion y ansiedad.

Legal Events

Date Code Title Description
FC Refusal